Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    Remdesivir | China

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04252664
Recruitment Status : Suspended (The epidemic of COVID-19 has been controlled well at present, no eligible patients can be recruitted.)
First Posted : February 5, 2020
Last Update Posted : April 15, 2020
Sponsor:
Collaborator:
Chinese Academy of Medical Sciences
Information provided by (Responsible Party):
Bin Cao, China-Japan Friendship Hospital

Brief Summary:

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay.

Given no specific antiviral therapy for COVID-19 and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate COVID-19.


Condition or disease Intervention/treatment Phase
COVID-19 SARS-CoV-2 Drug: Remdesivir Drug: Remdesivir placebo Phase 3

Detailed Description:

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay.

Whilst the outbreak is likely to have started from a zoonotic transmission event associated with a large seafood market that also traded in live wild animals, it soon became clear that person-to-person transmission was also occurring. The number of cases of COVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Mathematical models of the expansion phase of the epidemic suggested that sustained person-to-person transmission is occurring, and the R-zero is substantially above 1, the level required for a self-sustaining epidemic in human populations.

The clinical spectrum of COVID-19 appears to be wide, encompassing asymptomatic infection, a mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and even death. Although the per infection risk of severe disease remains to be determined, and may differ from the initial reports of 10-15%, the large number of cases in Wuhan has resulted in a large number of patients hospitalised with pneumonia. Progression from prodromal symptoms (usually fever, fatigue, cough) to severe pneumonia requiring supplementary oxygen support, mechanical ventilation, or in some cases ECMO appears to occur most commonly during the second week of illness in association with persistent viral RNA detection. This provides a window of opportunity to test candidate antiviral therapeutics.

This new coronavirus, and previous experiences with SARS and MERS-CoV, highlight the need for therapeutics for human coronavirus infections that can improve clinical outcomes, reduce risk of disease progression, speed recovery, and reduce the requirements for intensive supportive care and prolonged hospitalisation. In addition, treatments for mild cases to reduce the duration of illness and infectivity may also be of value were COVID-19 to become pandemic and/or endemic in human populations.

Given no specific antiviral therapy for COVID-19 and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate COVID-19.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 308 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.
Actual Study Start Date : February 12, 2020
Estimated Primary Completion Date : April 10, 2020
Estimated Study Completion Date : April 27, 2020

Arm Intervention/treatment
Experimental: Remdesivir group
active remdesivir
Drug: Remdesivir
RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Other Name: GS-5734

Placebo Comparator: Control group
Placebos matched remdesivir
Drug: Remdesivir placebo
RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.




Primary Outcome Measures :
  1. Time to Clinical recoveryTime to Clinical Recovery (TTCR) [ Time Frame: up to 28 days ]

    TTCR is defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours, or live hospital discharge, whichever comes first.

    Normalisation and alleviation criteria:

    • Fever - <37°C,
    • Respiratory rate - ≤24/minute on room air,
    • Oxygen saturation - >94% on room air,
    • Cough - mild or absent on a patient reported scale of severe, moderate, mild, absent.


Secondary Outcome Measures :
  1. All cause mortality [ Time Frame: up to 28 days ]
    baseline SpO2 during screening, PaO2/FiO2 <300mmHg or a respiratory rate ≥ 24 breaths per min without supplemental oxygen

  2. Frequency of respiratory progression [ Time Frame: up to 28 days ]
    Defined as SPO2≤ 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support.

  3. Time to defervescence (in those with fever at enrolment) [ Time Frame: up to 28 days ]
  4. Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate) [ Time Frame: up to 28 days ]
  5. Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,) [ Time Frame: up to 28 days ]
  6. Frequency of requirement for supplemental oxygen or non-invasive ventilation [ Time Frame: up to 28 days ]
  7. Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen [ Time Frame: up to 28 days ]
  8. Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve. [ Time Frame: up to 28 days ]
  9. Frequency of requirement for mechanical ventilation [ Time Frame: up to 28 days ]
  10. Frequency of serious adverse events [ Time Frame: up to 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years at time of signing Informed Consent Form
  2. Laboratory (RT-PCR) confirmed COVID-19.
  3. Lung involvement confirmed with chest imaging
  4. Hospitalised with:

    • Fever - ≥36.7℃ -axilla or Oral temperature ≥ 38.0 ℃ or ≥38.6°C tympanic or rectal or
    • And at least one of Respiratory rate >24/min Or Cough
  5. ≤8 days since illness onset
  6. Willingness of study participant to accept randomization to any assigned treatment arm.
  7. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.

Exclusion Criteria:

  1. Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.
  2. Severe liver disease (e.g. Child Pugh score ≥ C, AST>5 times upper limit)
  3. SaO2/SPO2≤94% in room air condition, or the Pa02/Fi02 ratio <300mgHg
  4. Known allergic reaction to remdesivir
  5. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
  6. Pregnant or breastfeeding, or positive pregnancy test in a predose examination
  7. Will be transferred to another hospital which is not the study site within 72 hours.
  8. Receipt of any experimental treatment for COVID-19 within the 30 days prior to the time of the screening evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04252664


Locations
Layout table for location information
China, Hubei
Jin Yin-tan hospital
Wuhan, Hubei, China, 100013
Sponsors and Collaborators
Capital Medical University
Chinese Academy of Medical Sciences
Layout table for additonal information
Responsible Party: Bin Cao, Professor, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier: NCT04252664    
Other Study ID Numbers: CAP-China remdesivir 1
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: April 15, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No